Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Amount of Mononuclear Phagocyte Infiltrate Does Not Predict Area of Experimental Choroidal Neovascularization (CNV).

Will-Orrego A, Qiu Y, Fassbender ES, Shen S, Aranda J, Kotagiri N, Maker M, Liao SM, Jaffee BD, Poor SH.

J Ocul Pharmacol Ther. 2018 Sep;34(7):489-499. doi: 10.1089/jop.2017.0131.

2.

Induction of Ocular Complement Activation by Inflammatory Stimuli and Intraocular Inhibition of Complement Factor D in Animal Models.

Crowley MA, Delgado O, Will-Orrego A, Buchanan NM, Anderson K, Jaffee BD, Dryja TP, Liao SM.

Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):940-951. doi: 10.1167/iovs.17-22605.

PMID:
29450541
3.

Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa.

MacLachlan TK, Milton MN, Turner O, Tukov F, Choi VW, Penraat J, Delmotte MH, Michaut L, Jaffee BD, Bigelow CE.

Mol Ther Methods Clin Dev. 2017 Dec 22;8:105-120. doi: 10.1016/j.omtm.2017.12.001. eCollection 2018 Mar 16.

4.

Specific correlation between the major chromosome 10q26 haplotype conferring risk for age-related macular degeneration and the expression of HTRA1.

Liao SM, Zheng W, Zhu J, Lewis CA, Delgado O, Crowley MA, Buchanan NM, Jaffee BD, Dryja TP.

Mol Vis. 2017 Jun 14;23:318-333. eCollection 2017.

5.

AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice.

Choi VW, Bigelow CE, McGee TL, Gujar AN, Li H, Hanks SM, Vrouvlianis J, Maker M, Leehy B, Zhang Y, Aranda J, Bounoutas G, Demirs JT, Yang J, Ornberg R, Wang Y, Martin W, Stout KR, Argentieri G, Grosenstein P, Diaz D, Turner O, Jaffee BD, Police SR, Dryja TP.

Mol Ther Methods Clin Dev. 2015 Jul 8;2:15022. doi: 10.1038/mtm.2015.22. eCollection 2015.

6.

Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation.

Poor SH, Qiu Y, Fassbender ES, Shen S, Woolfenden A, Delpero A, Kim Y, Buchanan N, Gebuhr TC, Hanks SM, Meredith EL, Jaffee BD, Dryja TP.

Invest Ophthalmol Vis Sci. 2014 Sep 9;55(10):6525-34. doi: 10.1167/iovs.14-15067.

PMID:
25205860
7.

Intra-articular injection of tumor necrosis factor-alpha in the rat: an acute and reversible in vivo model of cartilage proteoglycan degradation.

Malfait AM, Tortorella M, Thompson J, Hills R, Meyer DM, Jaffee BD, Chinn K, Ghoreishi-Haack N, Markosyan S, Arner EC.

Osteoarthritis Cartilage. 2009 May;17(5):627-35. doi: 10.1016/j.joca.2008.10.005. Epub 2008 Nov 1.

8.

A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.

Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, Hepperle M, Harriman G, Jaffee BD, Ocain TD, Xu Y.

J Pharmacol Exp Ther. 2006 Jun;317(3):989-1001. Epub 2006 Mar 8.

PMID:
16525037
9.

Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.

Xue CB, He X, Corbett RL, Roderick J, Wasserman ZR, Liu RQ, Jaffee BD, Covington MB, Qian M, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP.

J Med Chem. 2001 Oct 11;44(21):3351-4.

PMID:
11585440
10.

Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.

Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP.

J Med Chem. 2001 Aug 2;44(16):2636-60.

PMID:
11472217
11.

Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo.

Jaffee BD, Manos EJ, Collins RJ, Czerniak PM, Favata MF, Magolda RL, Scherle PA, Trzaskos JM.

Biochem Biophys Res Commun. 2000 Feb 16;268(2):647-51.

PMID:
10679258
12.

Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.

Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP.

Bioorg Med Chem Lett. 1999 May 3;9(9):1279-84.

PMID:
10340614
13.

Heteroatom- and carbon-linked biphenyl analogs of Brequinar as immunosuppressive agents.

Batt DG, Petraitis JJ, Sherk SR, Copeland RA, Dowling RL, Taylor TL, Jones EA, Magolda RL, Jaffee BD.

Bioorg Med Chem Lett. 1998 Jul 7;8(13):1745-50.

PMID:
9873427
14.

Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium.

Pitts WJ, Jetter JW, Pinto DJ, Orwat MJ, Batt DG, Sherk SR, Petraitis JJ, Jacobson IC, Copeland RA, Dowling RL, Jaffee BD, Gardner TL, Jones EA, Magolda RL.

Bioorg Med Chem Lett. 1998 Feb 3;8(3):307-12.

PMID:
9871675
15.

Brequinar and brequinar analogues in rat allo- and xenotransplantation.

Schuurman HJ, Tanner M, Pally C, Jaffee BD.

Transplant Proc. 1998 Aug;30(5):2240-3. No abstract available.

PMID:
9723456
16.

Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.

Xue CB, He X, Roderick J, DeGrado WF, Cherney RJ, Hardman KD, Nelson DJ, Copeland RA, Jaffee BD, Decicco CP.

J Med Chem. 1998 May 21;41(11):1745-8. No abstract available.

PMID:
9599225
17.

Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy.

DeSilva DR, Jones EA, Favata MF, Jaffee BD, Magolda RL, Trzaskos JM, Scherle PA.

J Immunol. 1998 May 1;160(9):4175-81.

18.

Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, et al.

Nature. 1995 Nov 23;378(6555):406-9.

PMID:
7477380
19.

Novel mechanisms of brequinar sodium immunosuppression on T cell activation.

Forrest TL, Ware RE, Howard T, Jaffee BD, Denning SM.

Transplantation. 1994 Oct 27;58(8):920-6.

PMID:
7940736
20.

Inhibition of in vitro immunoglobulin production by a novel immunosuppressive drug brequinar sodium.

Moudgil A, Toyoda M, Wang SJ, Jaffee BD, Cramer DV, Makowka L, Jordan S.

Transplant Sci. 1994 Sep;4(1):116-8. No abstract available.

PMID:
7528627
21.

Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation.

Collins BH, Areford ML, Fabian MA, Jaffee BD, Bollinger RR.

Transplant Proc. 1993 Jun;25(3 Suppl 2):37-9. No abstract available.

PMID:
8516941
22.

Brequinar sodium: inhibition of dihydroorotic acid dehydrogenase, depletion of pyrimidine pools, and consequent inhibition of immune functions in vitro.

Simon P, Townsend RM, Harris RR, Jones EA, Jaffee BD.

Transplant Proc. 1993 Jun;25(3 Suppl 2):77-80. No abstract available.

PMID:
8390742
23.

The unique immunosuppressive activity of brequinar sodium.

Jaffee BD, Jones EA, Loveless SE, Chen SF.

Transplant Proc. 1993 Jun;25(3 Suppl 2):19-22. No abstract available.

PMID:
7685954
24.

Effects of brequinar sodium on cynomolgus monkeys: immunosuppression and pharmacokinetics.

Jaffee BD, Jones EA, Zajac I, Magolda RL, Cramer DV, Makowka L.

Transplant Proc. 1993 Feb;25(1 Pt 1):710-1. No abstract available.

PMID:
8438449
25.

Prevention of liver allograft rejection in rats by a short course of therapy with Brequinar Sodium.

Cramer DV, Knoop M, Chapman FA, Wa GD, Jaffee BD, Makowka L.

Transplantation. 1992 Oct;54(4):752-3. No abstract available.

PMID:
1412774
26.

The prolongation of concordant hamster-to-rat cardiac xenografts by brequinar sodium.

Cramer DV, Chapman FA, Jaffee BD, Zajac I, Hreha-Eiras G, Yasunaga C, Wu GD, Makowka L.

Transplantation. 1992 Sep;54(3):403-8.

PMID:
1412717
27.

Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium.

O'Neill JK, Baker D, Davison AN, Maggon KK, Jaffee BD, Turk JL.

J Neuroimmunol. 1992 May;38(1-2):53-62.

PMID:
1577953
28.

The effect of a new immunosuppressive drug, brequinar sodium, on concordant hamster-to-rat cardiac xenografts.

Cramer DV, Chapman FA, Jaffee BD, Eiras-Hreha G, Yasunaga C, Wu GD, Makowka L.

Transplant Proc. 1992 Apr;24(2):720-1. No abstract available.

PMID:
1566499
29.

The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat.

Cramer DV, Chapman FA, Jaffee BD, Jones EA, Knoop M, Hreha-Eiras G, Makowka L.

Transplantation. 1992 Feb;53(2):303-8.

PMID:
1531394
30.

Hepatic lesions in murine chronic graft-versus-host disease to minor histocompatibility antigens. A reproducible model of nonsuppurative destructive cholangitis.

Vierling JM, Ruderman WB, Jaffee BD, Fennell RH Jr, Claman HN.

Transplantation. 1989 Oct;48(4):717-8. No abstract available.

PMID:
2799935
31.

The effect of immunomodulating drugs on adjuvant-induced arthritis in Lewis rats.

Jaffee BD, Kerr JS, Jones EA, Giannaras JV, McGowan M, Ackerman NR.

Agents Actions. 1989 Jun;27(3-4):344-6.

PMID:
2801321
32.

Antiinflammatory consequences of 5-lipoxygenase inhibition.

Ackerman NR, Arner EC, Galbraith W, Harris RR, Jaffee BD, Mackin WM.

Adv Prostaglandin Thromboxane Leukot Res. 1986;16:47-62. No abstract available.

PMID:
2949564
33.
34.
35.

Desensitization of contact allergy to DNFB in mice. I. Description of a model system.

Claman HN, Jaffee BD.

J Immunol. 1983 Dec;131(6):2682-6.

PMID:
6227661
36.
37.

Regional lymph node x-radiation suppresses allograft rejection.

Maguire HC Jr, Jaffee BD.

Arch Dermatol Res. 1982;272(3-4):283-91.

PMID:
7165338

Supplemental Content

Loading ...
Support Center